Literature DB >> 10734111

Mammalian Notch1 is modified with two unusual forms of O-linked glycosylation found on epidermal growth factor-like modules.

D J Moloney1, L H Shair, F M Lu, J Xia, R Locke, K L Matta, R S Haltiwanger.   

Abstract

Notch is a large cell-surface receptor known to be an essential player in a wide variety of developmental cascades. Here we show that Notch1 endogenously expressed in Chinese hamster ovary cells is modified with O-linked fucose and O-linked glucose saccharides, two unusual forms of O-linked glycosylation found on epidermal growth factor-like (EGF) modules. Interestingly, both modifications occur as monosaccharide and oligosaccharide species. Through exoglycosidase digestions we determined that the O-linked fucose oligosaccharide is a tetrasaccharide with a structure identical to that found on human clotting factor IX: Sia-alpha2,3-Gal-beta1, 4-GlcNAc-beta1,3-Fuc-alpha1-O-Ser/Thr. The elongated form of O-linked glucose appears to be a trisaccharide. Notch1 is the first membrane-associated protein identified with either O-linked fucose or O-linked glucose modifications. It also represents the second protein discovered with an elongated form of O-linked fucose. The sites of glycosylation, which fall within the multiple EGF modules of Notch, are highly conserved across species and within Notch homologs. Since Notch is known to interact with its ligands through subsets of EGF modules, these results suggest that the O-linked carbohydrate modifications of these modules may influence receptor-ligand interactions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10734111     DOI: 10.1074/jbc.275.13.9604

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  114 in total

Review 1.  Notch signaling in mammary development and oncogenesis.

Authors:  Robert Callahan; Sean E Egan
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-04       Impact factor: 2.673

Review 2.  Role of glycans and glycosyltransferases in the regulation of Notch signaling.

Authors:  Hamed Jafar-Nejad; Jessica Leonardi; Rodrigo Fernandez-Valdivia
Journal:  Glycobiology       Date:  2010-04-05       Impact factor: 4.313

3.  Deciphering the Fringe-Mediated Notch Code: Identification of Activating and Inhibiting Sites Allowing Discrimination between Ligands.

Authors:  Shinako Kakuda; Robert S Haltiwanger
Journal:  Dev Cell       Date:  2017-01-12       Impact factor: 12.270

4.  O-glucose trisaccharide is present at high but variable stoichiometry at multiple sites on mouse Notch1.

Authors:  Nadia A Rana; Aleksandra Nita-Lazar; Hideyuki Takeuchi; Shinako Kakuda; Kelvin B Luther; Robert S Haltiwanger
Journal:  J Biol Chem       Date:  2011-07-08       Impact factor: 5.157

5.  Notch-dependent control of myelopoiesis is regulated by fucosylation.

Authors:  Lan Zhou; Lebing Wei Li; Quanjian Yan; Bronislawa Petryniak; Yunfang Man; Charles Su; Jeongsup Shim; Stephanie Chervin; John B Lowe
Journal:  Blood       Date:  2008-03-21       Impact factor: 22.113

6.  Signal Transduction: Notch catches a Jagged edge.

Authors:  Stephen C Blacklow
Journal:  Nat Chem Biol       Date:  2017-05-17       Impact factor: 15.040

7.  Fringe-mediated extension of O-linked fucose in the ligand-binding region of Notch1 increases binding to mammalian Notch ligands.

Authors:  Paul Taylor; Hideyuki Takeuchi; Devon Sheppard; Chandramouli Chillakuri; Susan M Lea; Robert S Haltiwanger; Penny A Handford
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-06       Impact factor: 11.205

Review 8.  Biological functions of fucose in mammals.

Authors:  Michael Schneider; Esam Al-Shareffi; Robert S Haltiwanger
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

Review 9.  Role of unusual O-glycans in intercellular signaling.

Authors:  Kelvin B Luther; Robert S Haltiwanger
Journal:  Int J Biochem Cell Biol       Date:  2008-10-08       Impact factor: 5.085

Review 10.  Notch inhibitors for cancer treatment.

Authors:  Ingrid Espinoza; Lucio Miele
Journal:  Pharmacol Ther       Date:  2013-02-28       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.